Blum&Grob advised the industrial investor Siemens Healthineers in the Series G Financing Round of the biotech-startup and ETH spin-off BiognoSYS AG which also included existing institutional and private shareholders/investors. The fresh funds will be invested into building a new GCP-certified facility in Switzerland, increasing current operational capacity as well as enhancing the company’s sales force, further expanding its commercial presence in the US (both East and West Coast), Europe, and Asia.

Weitere Artikel